Study shows AstraZeneca’s Covid-19 booster dose protects against Omicron

Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant

Three doses of Pfizer-BioNTech vaccine protects against Omicron: Study

According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron

AstraZeneca’s Covid-19 drug offers 83% protection over six months

Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths

Trivitron launches SpaceD radiation protection aprons

These aprons utilise phase change materials that absorb, store and release heat for optimal thermal comfort

Lonza surges on biologics boom

Expands manufacturing push & locks in major growth deals

Moderna’s mRNA flu vaccine outperforms standard shot in Phase 3 trial

NEJM study shows strong protection across strains

Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics

The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy

CARE Hospitals performs rare organ-preserving pancreatic surgery

Complex tumour removed in a young patient without major pancreatic loss, reducing risk of lifelong diabetes

SetPoint Medical launches first-in-human MS pilot study using implanted nerve stimulation device

Gufic Biosciences deepens global oncology push with fresh investment in Australia’s Selvax

Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology